Nuvectis Pharma, Inc.
NVCT
$9.44
-$0.05-0.53%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 18.53M | 17.17M | 18.12M | 19.46M | 19.13M |
| Total Receivables | -- | -- | -- | -- | -- |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | -- | -- | -- | -- | -- |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 74.00K | 138.00K | 182.00K | 250.00K | 59.00K |
| Total Current Assets | 18.61M | 17.31M | 18.30M | 19.71M | 19.19M |
|
|
|||||
| Total Current Assets | 18.61M | 17.31M | 18.30M | 19.71M | 19.19M |
| Net Property, Plant & Equipment | -- | -- | -- | -- | -- |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | -- | -- | -- | -- | -- |
| Total Assets | 18.61M | 17.31M | 18.30M | 19.71M | 19.19M |
|
|
|||||
| Total Accounts Payable | 2.50M | 2.26M | 1.85M | 1.76M | 2.77M |
| Total Accrued Expenses | 6.40M | 4.06M | 3.92M | 3.93M | 4.21M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Current Liabilities | -- | -- | -- | -- | -- |
| Total Current Liabilities | 8.89M | 6.32M | 5.77M | 5.69M | 6.98M |
|
|
|||||
| Total Current Liabilities | 8.89M | 6.32M | 5.77M | 5.69M | 6.98M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | -- | -- | -- | -- | -- |
| Total Liabilities | 8.89M | 6.32M | 5.77M | 5.69M | 6.98M |
|
|
|||||
| Common Stock & APIC | 82.96M | 77.99M | 75.37M | 72.44M | 66.45M |
| Retained Earnings | -73.25M | -67.00M | -62.84M | -58.42M | -54.25M |
| Treasury Stock & Other | -- | -- | -- | -- | -- |
| Total Common Equity | 9.71M | 10.99M | 12.53M | 14.02M | 12.20M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 9.71M | 10.99M | 12.53M | 14.02M | 12.20M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 9.71M | 10.99M | 12.53M | 14.02M | 12.20M |
|
|
|||||
